Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 67
7.
J Eur Acad Dermatol Venereol ; 33(8): 1535-1540, 2019 Aug.
Article En | MEDLINE | ID: mdl-30972880

BACKGROUND: Mutations in kinetochore gene KNSTRN accelerate the development of cutaneous squamous cell carcinoma (SCC) and may correlate with different histological classifications of actinic keratosis (AKs). OBJECTIVE: To determine KNSTRN gene mutation frequency in healthy skin (HS), actinically damaged skin (ADS), in AKs with different histomorphological gradings and invasive SCCs. METHODS: All samples were histologically evaluated. AK lesions were additionally classified according to their upwards (AK I-III) and downwards (PRO I-III) directed growth pattern. Mutation analyses of all samples were performed using the Sanger method. RESULTS: With one exception, all detected mutations in KNSTRN gene showed an alanine-to-glutamate substitution at codon 40 (p.Ala40Glu). p.Ala40Glu mutation was found in 6.9% (2/29) of HS, in 16.1% (5/31) of ADS, in 18.3% (20/109) of AKs and in 30.0% (9/30) of invasive SCCs. Further stratification of AKs using the common AK classification of Röwert-Huber revealed the p.Ala40Glu mutation in 14.7% (5/43), 13.3% (4/30) and 24.4% (11/45) (AK I, II and III). In contrast, the new PRO classification showed a distribution of 3.6% (1/28) in PRO I, 21.7% (13/60) in PRO II and 28.6% (6/21) in PRO III. Mutation frequency in HS showed significant differences compared to AKs classified as PRO III and invasive SCCs (P < 0.05). In contrast, there were no statistically significant differences between HS and AKs when classified according to Röwert-Huber. CONCLUSIONS: Recurrent somatic mutation p.Ala40Glu in KNSTRN gene is associated with basal proliferating AKs in accordance with invasive SCCs. This supports the impact of basal proliferative pattern in terms of progression.


Carcinoma, Squamous Cell/genetics , Cell Cycle Proteins/genetics , Keratosis, Actinic/genetics , Kinetochores , Microtubule-Associated Proteins/genetics , Mutation , Skin Neoplasms/genetics , Carcinoma, Squamous Cell/pathology , Disease Progression , Humans , Keratosis, Actinic/pathology , Retrospective Studies , Skin Neoplasms/pathology
8.
J Eur Acad Dermatol Venereol ; 33(6): 1092-1097, 2019 Jun.
Article En | MEDLINE | ID: mdl-30887613

BACKGROUND: Actinic keratoses (AKs) can histologically be classified by the extent of atypical keratinocytes throughout the epidermis or their pattern of basal proliferation. Currently, no data on the inter-rater reliability of both scores is available. OBJECTIVE: To evaluate the inter-rater reliability of the two classification schemes; histological grade (AK I-III) and basal proliferation (PRO I-III). METHODS: Histological images of 54 AKs were classified by 21 independent dermatopathologists with regard to basal proliferation (PRO I-III), histological grade (AK I-III) and assumed risk of progression into invasive carcinoma. RESULTS: Overall, of the 54 AKs 16.7% (9/54) were classified as AK I, 66.7% (36/54) as AK II, and 16.7% (9/54) as AK III. With regards to basal growth pattern, 25.9% (14/54) were classified as PRO I, 42.6% (23/54) as PRO II, and 31.5% (17/54) as PRO III. We observed a highly significant inter-rater reliability for PRO-grading (P < 0.001) which was higher than for AK-grading (Kendall's W coefficient: AK = 0.488 vs. PRO = 0.793). We found substantial agreement for assumed progression risk for AKs with worsening basal proliferation (k = 0.759) compared to moderate agreement (k = 0.563) for different AK-gradings. CONCLUSIONS: Histological classification of basal growth pattern (PRO) showed higher inter-rater reliability compared to the established classification of atypical keratinocytes throughout epidermal layers. Moreover, experienced dermatopathologists considered basal proliferation to be more important in terms of progression risk than upwards directed growth patterns. It should be considered to classify AKs according to their basal proliferation pattern (PRO I-III).


Keratosis, Actinic/classification , Observer Variation , Adult , Humans , Keratosis, Actinic/pathology , Middle Aged
9.
Pathologe ; 39(Suppl 2): 355-356, 2018 Dec.
Article De | MEDLINE | ID: mdl-30229282
11.
Ophthalmologe ; 114(8): 737-740, 2017 Aug.
Article De | MEDLINE | ID: mdl-27595883

A 52-year-old male caucasian patient presented with a limbal subconjunctival pigmentation of unknown origin with progressive enlargement over the past years. Differential diagnoses included a malignant melanocytic lesion; therefore, an excisional biopsy was performed. Prior investigations showed no ciliary body or anterior chamber angle involvement. Histological and immunohistochemical analysis revealed the rare diagnosis of a scleral nevus. The clinical, histological and immunohistochemical findings as well as the relevant differential diagnoses are discussed.


Eye Neoplasms/diagnosis , Nevus, Pigmented/diagnosis , Scleral Diseases/diagnosis , Animals , Diagnosis, Differential , Disease Progression , Eye Neoplasms/pathology , Eye Neoplasms/surgery , Humans , Male , Middle Aged , Rabbits , Sclera/pathology , Sclera/surgery , Scleral Diseases/pathology , Scleral Diseases/surgery , Slit Lamp Microscopy
12.
Ophthalmologe ; 113(12): 1070-1073, 2016 Dec.
Article De | MEDLINE | ID: mdl-27033228

Neuromas of the eyelid margin and lower lip were diagnosed in a 29-year-old man. As the combination of these lesions is indicative of multiple endocrine neoplasia type 2b (MEN2b) syndrome, the presence of a medullary thyroid carcinoma or a pheochromocytoma were excluded by a systematic work-up. A mutation in the RET proto-oncogene was not found by genetic testing. In summary, the patient presented with neuromas on the eyelid margin and lower lip without an association to a syndrome; however, patients with such neuromas should be screened for MEN2b syndrome due to the high mortality.


Eyelid Neoplasms/diagnosis , Eyelid Neoplasms/genetics , Lip Neoplasms/diagnosis , Lip Neoplasms/genetics , Neuroma/diagnosis , Neuroma/genetics , Adult , Diagnosis, Differential , Humans , Male , Multiple Endocrine Neoplasia Type 2b/diagnosis , Multiple Endocrine Neoplasia Type 2b/genetics , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/genetics , Proto-Oncogene Mas
13.
J Eur Acad Dermatol Venereol ; 30(8): 1303-7, 2016 Aug.
Article En | MEDLINE | ID: mdl-26955898

BACKGROUND: There are several clinical and histological classification systems for grading actinic keratosis (AK) lesions. The Olsen clinical classification scheme grades AK lesions according to their thickness and degree of hyperkeratosis (grades 1-3). The Roewert-Huber histological classification system grades AK lesions based on the extent of epidermal atypical keratinocytes (AK I-III). OBJECTIVE: The aim of this study was to determine whether there is a correlation between these clinical and histological AK classification schemes. METHODS: One AK lesion from patients in three pivotal clinical studies and routine practice was assessed clinically and histologically. A match in grading was defined as Olsen grade 1 being classified histologically as AK I, Olsen grade 2 as AK II and Olsen grade 3 as AK III. RESULTS: Of the 892 lesions included, 29.0% were classified as Olsen grade 1, 59.6% as Olsen grade 2 and 11.3% as Olsen grade 3; 19.2% were histologically classified as AK I, 69.6% as AK II and 11.2% as AK III. Only 480 lesions (53.8%) had a matching clinical and histological classification. Of these matches, most were 'Olsen grade 2 = AK II' (83.1%). The Spearman's rank correlation coefficient for clinical and histological classification was r = 0.0499 (P = 0.137). CONCLUSIONS: Clinical classification of AK lesions using the system of Olsen does not accurately match histological classification of the same lesions using the system of Roewert-Huber. Consequently, it is not possible to draw conclusions about the histology of AK lesions from their clinical appearance. This finding reinforces the need to treat all AK lesions as well as field cancerization.


Keratosis, Actinic/pathology , Aged , Female , Humans , Male , Middle Aged
14.
Pathologe ; 36(1): 16-29, 2015 Feb.
Article De | MEDLINE | ID: mdl-25663185

Actinic (solar) keratosis is an intraepidermal squamous neoplasm of sun-damaged skin and by far the most frequent neoplastic skin lesion. A subdivison into three grades has been proposed with increasing acceptance not least because of the therapeutic consequences. The transition to invasive squamous cell carcinoma is reported in 5-10 % and with immunosuppression in 30 % of patients.Bowen's disease is a variant of squamous cell carcinoma in situ of the skin and the mucocutaneous junction. The differentiation from bowenoid papulosis as a lesion associated with human papillomavirus (HPV), actinic (solar) keratosis grade III, intraepidermal poroid lesions and in cases of clonal type from clonal seborrhoic keratosis and Paget's disease is very important.Keratoacanthoma is currently uniformly interpreted as a variant of highly differentiated squamous cell carcinoma of the skin with clinical and histomorphological characteristics. Clinically keratoacanthoma erupts rapidly and is capable of resolving spontaneously. Histologically, there is a characteristic growth pattern and various stages of regression. The final histomorphological diagnosis needs the entire specimen.Squamous cell carcinoma of the skin is the second most common type of skin cancer following basal cell carcinoma. With respect to reccurrencies and risk of metastases the subtyping of cutaneous squamous cell carcinoma is very important. The classification system of the Union Internationale Contra le Cancer (UICC) is based solely on the anatomical spread and the classification system of the American Joint Committee on Cancer (AJCC) also considers so-called high-risk features in the staging between stages I and II.


Bowen's Disease/pathology , Carcinoma, Squamous Cell/pathology , Keratoacanthoma/pathology , Keratosis, Actinic/pathology , Skin Neoplasms/pathology , Disease Progression , Humans , Neoplasm Grading , Neoplasm Invasiveness , Neoplasm Recurrence, Local/pathology , Risk Factors , Skin/pathology
16.
Pathologe ; 36(1): 46-50, 52, 2015 Feb.
Article De | MEDLINE | ID: mdl-25591417

Dysplastic nevus is still a controversial entity both clinically and histologically. The occurrence of dysplastic nevus especially in the context of dysplastic nevus cell syndrome is associated with an increased risk for melanoma. The following minimal histological criteria should be fulfilled: nests of melanocytes varying in size and shape, bridging and confluent, proliferation of single melanocytes basal and suprabasal, cytoplasmic and nuclear atypia of melanocytes and subepidermal fibroplasia. The biological behavior (common nevus variant or precursor of melanoma?) is difficult to evaluate by presently available methods. The further development of new molecular biology techniques may allow a better prognosis of dysplastic nevi in an objective and reproducible manner. Against this background complete excision followed by clinical surveillance has to be recommended for the routine practice.


Dysplastic Nevus Syndrome/pathology , Nevus, Pigmented/pathology , Cell Proliferation , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Diagnosis, Differential , Dysplastic Nevus Syndrome/genetics , Dysplastic Nevus Syndrome/surgery , Humans , Melanocytes/pathology , Melanoma/genetics , Melanoma/pathology , Melanoma/surgery , Molecular Diagnostic Techniques , Nevus, Pigmented/genetics , Nevus, Pigmented/surgery , Risk Assessment , Skin/pathology
17.
Dermatology ; 228(1): 24-6, 2014.
Article En | MEDLINE | ID: mdl-24135797

Lesion biopsy is currently used to diagnose erythroplasia of Queyrat (EQ), a rare squamous cell carcinoma in situ of the glans penis, or to determine whether the cancer is invasive, although the results only apply to the area from which the biopsy is taken. In this case report, we illustrate for the first time the use of optical coherence tomography (OCT) in imaging the entire lesion in a patient with EQ. The results confirmed that the patient had in situ rather than invasive carcinoma. Consequently, non-invasive treatment with imiquimod 5%, a topical immunomodulator with antitumour and antiviral properties, was initiated. Excellent clinical results were observed 4 weeks after the patient had been treated with imiquimod 5% three times a week for 8 weeks, which were confirmed using OCT imaging. One year later, there was still no evidence of pathology either clinically or via OCT imaging. OCT imaging should be used in conjunction with biopsy evaluation in the diagnostic work-up of EQ. Imiquimod 5% is a suitable treatment for patients with EQ, and the treatment response can be evaluated using OCT.


Carcinoma in Situ/pathology , Carcinoma, Squamous Cell/pathology , Erythroplasia/pathology , Penile Neoplasms/pathology , Tomography, Optical Coherence , Administration, Cutaneous , Aminoquinolines/therapeutic use , Antineoplastic Agents/therapeutic use , Carcinoma in Situ/drug therapy , Carcinoma, Squamous Cell/drug therapy , Erythroplasia/drug therapy , Humans , Imiquimod , Male , Middle Aged , Penile Neoplasms/drug therapy
18.
J Eur Acad Dermatol Venereol ; 24(3): 258-63, 2010 Mar.
Article En | MEDLINE | ID: mdl-19709346

BACKGROUND: Actinic keratoses (AKs) are frequently diagnosed in dermatological patients. As they represent in situ carcinomas, effective treatment is required. OBJECTIVES: We investigated the effect of topical 3.0% diclofenac in 2.5% hyaluronic acid gel on AK. METHODS: Sixty-five patients with AKs were clinically evaluated before and after 3 months' treatment with topical 3.0% diclofenac in 2.5% hyaluronic gel. Biopsy specimens were taken and stained with haematoxylin-eosin and immunohistological markers. Specimens were evaluated for histological type of AKs using the AK classification scheme suggested by Röwert-Huber et al. [(early) in situ squamous cell carcinoma type AK Grade I-III], number of mitoses per high-power field and expression of immunohistological markers. RESULTS: Complete clinical resolution was observed in 11 patients (16.9%). A significant (P<0.001) downgrading of AK grade was observed. Complete histological resolution was achieved in 15 patients (23.1%). The number of mitoses per high-power field was reduced significantly (P<0.001). The expression of anti-p53-antibody decreased significantly (P=0.009), as did the expression of anti-MiB-1 antibody (P=0.021). CONCLUSIONS: 3.0% diclofenac in 2.5% hyaluronic acid gel causes regression of signs of cancerous transformation after 3 months' therapy.


Cell Transformation, Neoplastic/drug effects , Diclofenac/administration & dosage , Hyaluronic Acid/administration & dosage , Keratosis, Actinic/drug therapy , Precancerous Conditions/prevention & control , Skin Neoplasms/prevention & control , Skin/pathology , Adjuvants, Immunologic/administration & dosage , Administration, Topical , Aged , Aged, 80 and over , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cell Transformation, Neoplastic/pathology , Disease Progression , Female , Follow-Up Studies , Gels , Humans , Keratosis, Actinic/pathology , Male , Middle Aged , Precancerous Conditions/pathology , Skin Neoplasms/pathology , Treatment Outcome
19.
Hautarzt ; 58(7): 611-4, 2007 Jul.
Article De | MEDLINE | ID: mdl-17464490

A 15-year-old patient developed scleroderma en coup de sabre on right temple at 5 years of age. Multiple treatments (3 cycles of intravenous penicillin, topical glucocorticosteroids, topical calcipotriol, and cream PUVA phototherapy combined with topical calcipotriol) produced no improvement. The patient suffered greatly from the psychosocial stigmatization, so that the entire lesion was resected at 14 years of age. One year after the operation a thin non-sclerotic scar was present; tiny lateral areas of sclerosis not included in the operative field were unchanged. The operation greatly improved the patient's daily life. The surgical therapy of scleroderma en coup de sabre offers an interesting therapeutic alternative.


Scleroderma, Localized/surgery , Administration, Topical , Adolescent , Calcitriol/administration & dosage , Calcitriol/analogs & derivatives , Dermatologic Agents/administration & dosage , Follow-Up Studies , Glucocorticoids/administration & dosage , Humans , Injections, Intravenous , Male , PUVA Therapy , Penicillins/administration & dosage , Time Factors , Treatment Outcome
20.
Pathologe ; 27(1): 53-6, 2006 Feb.
Article De | MEDLINE | ID: mdl-16362261

Malignant tumors are increasingly being treated with therapeutic agents having molecular mechanisms of action (so-called biologics). These include therapeutic agents for the blockade of epidermal growth factor receptor (EGFR). The adverse drug reaction profile associated with EGFR inhibitors is dominated by cutaneous lesions. Most common are acneiform skin reactions followed by xerosis, eczema and changes to the hair and nails. The cutaneous changes vary greatly between individuals and may be relatively insignificant. However, they may also prevent continuation of therapy. During the use of EGFR inhibitors, a correlation was observed between the severity of cutaneous changes and the effectiveness of the therapeutic agent, a finding potentially useful for individual dose adjustment.


Antineoplastic Agents/therapeutic use , ErbB Receptors/antagonists & inhibitors , Neoplasms/drug therapy , Skin/pathology , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/adverse effects , Cetuximab , Humans , Skin/drug effects
...